Trade Mark Journal No.2026/020 15 May 2026

UK00004377455 23 April 2026 (5)

FYSTARZI

International priority date claimed: 18 February 2026 (United States of America) (99659574)

Class 5: Gene therapy products, namely, genetically engineered tissues for transplant purposes; Pharmaceutical preparations for gene therapy for the treatment of ocular disease, such as Stargardt Disease; Pharmaceutical preparations for gene therapy for the treatment of Stargardt Disease.

Ocugen Inc.

Representative: Withers LLP